Scancell’s dilemma delayed
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
Accelerated path closes for Moderna/Merck’s immunotherapy
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
BioNTech claims a FixVac win
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
